(Q44418300)

English

Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus

scientific article published on 23 February 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

type-1 diabetes

0 references

1 reference

based on heuristic

inferred from title

author name string

G Luippold

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

T Klein

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

M Mark

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

R Grempler

4

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

23 February 2012

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

601-607

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Type 1 diabetes: new perspectives on disease pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Natural history of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Hypoglycemia in diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire Register of diabetes in children and young adults

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

SGLT2 inhibition--a novel strategy for diabetes treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Glucose handling by the kidney

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

SGLT2 mediates glucose reabsorption in the early proximal tubule.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Learning from glycosuria

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Kidney in diabetes: from organ damage target to therapeutic target.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01569.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2012.01569.X

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44418300&oldid=2022483323"